CD274 and neoplasm: The clinically approved mode of ICI delivery largely accounts for this phenomenon since mAb infused into patients does not selectively bind to PD-1/PD-L1 in tumors, and IV administration does not favor the accumulation of mAb in tumor tissues [104].